model updat abax acquisit
could close earli wednesday
abax acquisit may close aug ahead schedul
follow expir wait period hsr anti-trust act juli
believ zoeti acquisit abaxi announc may could close earli
wednesday august assum approv abaxi sharehold juli vote
well-ahead prior expect management indic deal would close end
formal updat model reflect deal accret remind
abaxi competitor anim health ah point-of-car diagnost dx
market market share behind market leader idexx lab
share overal remain posit deal believ give beachhead
posit adjac high-growth estim high-singl digit revenu growth
vertic pleas see pg addit detail abax ah dx market
rais estim po reflect abaxi addit
rais sale adj ep estim
respect account august
abaxi deal close impli accret
off-set higher interest expens fewer share buyback driven higher forecast
po base adj ep goe reiter buy rate
beachhead high-growth ah dx question remain
zoeti talk extens develop larger presenc ah dx market
believ deal would instantli provid substanti market share instal
base instrument oppos longer organ build-out ah dx space
grow around annual see strongest upsid intern market
strong presenc around sale abax
under-penetrated ou revenu well synergi
rx dx part busi howev sever key question remain includ
abaxiss human healthcar busi revenu
believ spin/sal like well relationship exist abax
distributor sale forc align look answer detail incl
updat guidanc zoetiss earn call aug estimate
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
zoeti global leader discoveri
develop manufactur
commerci anim health medicin
vaccin product companion
anim market well-diversifi portfolio
product line span eight core
speci five therapeut categori directli
market countri industri
believ zoeti benefit rise
demand companion product anim
health product particularli emerg market
new product product line extens
expand ancillari servic offer greater
oper work capit effici
opportunist invest acquisit and/or
partnership supplement growth
balanc sheet still good shape abax purchas
beyond zoetiss robust organ revenu growth yoy
earn power mid-teen multi-year compound-annual-growth-rate believ compani strong free cash
flow capit deploy option distinguish zoeti one
top name coverag univers prior deal zoeti net debt ttm ebitda
net leverag approxim purchas fund cash
hand increment new debt expect net leverag post-deal close
return gross debt ttm ebitda end
would favor posit balanc sheet capit alloc
believ prioriti go forward continu invest busi
commerci organ includ increment sale forc dx busi
manufactur follow tuck-in anim health adjac return
excess capit sharehold via dividend share buyback repurchas
stock approxim left latest share
see deal modestli accret adj ep estim
accret mix revenu cost synergi believ cost synergi
like come primarili gross margin expans suppli chain improv
reduc duplic compani cost oppos cut abaxiss sale forc
notabl estim assum zoeti retain abaxi human health busi
piccolo
summari bofaml model chang
tabl summari bofaml zoeti estim chang
million sale abaxi one leader anim health
diagnost space provid in-hous diagnost instrument system relat
consum servic inform manag system primarili
veterinari market well sell point-of-car poc dx product human
health market estim abaxi share approxim
in-hous test veterinari market grow annual
howev shown compani averag growth rate around
compani seen share loss competitor name idexx lab
recent abaxi seen sharp return strong growth revenu
growth heel sever new product launch
on-going restructur sale organ go-to-market strategi
notabl product launch includ urin chemistri analyz vetscan ua
urin sediment analyz vetscan sa rapid assay test howev
major abaxi revenu continu tie recur revenu core
clinic chemistri instrument vetscan total sale improv
growth part busi critic order sustain elev top-lin
perform wave new product introduct begin lap prior-year comp
late
geograph product type speci mix
rel zoeti abaxi much concentr us north america
sale vs zoeti chart beyond veterinari product portfolio abaxi
also gener around annual revenu total human
diagnost market via piccolo relat consum chart
includ product use orbo process extend
po base ep estim back dcf
assum wacc termin growth rate modest premium
compani broader blend peer group in-lin current multipl
justifi given upsid new product launch increment capit deploy
margin expans opportun defens natur busi
downsid risk price object competit select market weaker demand
anim health product regulatori issu macroeconom condit currenc risk
headwind relat regul antibiot use anim feed addit
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
